Author(s): Elizabeth Eldhose, B. Gowramma, Manal Mohammed, R. Kalirajan, L. Kaviarasan

Email(s): gowrammab@rediffmail.com , gowrammab@jssuni.edu.in

DOI: 10.5958/0974-360X.2019.00524.9   

Address: Elizabeth Eldhose1, B. Gowramma1*, Manal Mohammed2, R. Kalirajan1, L. Kaviarasan1
1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Udhagamandalam, Tamilnadu,
2Department of Pharmaceutical Chemistry, KTN College of Pharmacy, Kerala.
*Corresponding Author

Published In:   Volume - 12,      Issue - 6,     Year - 2019


ABSTRACT:
Breast Cancer, the most common cancer observed in women around the world[1], accounts for 12% of all new cancer cases and nearly 25% of all cancers in women[2]. Breast Cancer, a heterogenous disease, is evident over a broad differentiation in phenotypes and morphological profiles, with an after effect of various clinical behaviours[3]. From an estimated 1 million breast cancer cases diagnosed worldwide, 170,000 are of triple negative phenotype (15-20%)[4]. Triple Negative Breast Cancer (TNBC) is a substantially histopathological category based, where there is deficiency of expression of hormone receptors (ER and PR) as well as no transmutation of human epidermal growth factor receptor type 2 (HER2)[3]. They are characterized by poor prognosis and aggressiveness construed by low five-year survival and high recurrence rates after adjuvant therapy. TNBC share arresting correlation with basal-like breast cancers. It is observed with high frequency of BRCA1 mutations and a heightened Ki-67 expression. Taxanes and/or platinum compounds and PARP 1 inhibitors are a good choice of treatment for TNBC[4]. The intent of this review is to highlight the relevance of PARP 1 inhibitors on TNBC and display an in depth discussion regarding these futuristic inhibitors.


Cite this article:
Elizabeth Eldhose, B. Gowramma, Manal Mohammed, R. Kalirajan, L. Kaviarasan. Translational Chemotherapy for triple negative Breast Cancer - A Review on significance of poly (ADP-ribose) polymerase 1 (PARP 1) inhibitors. Research J. Pharm. and Tech. 2019; 12(6):3098-3104. doi: 10.5958/0974-360X.2019.00524.9

Cite(Electronic):
Elizabeth Eldhose, B. Gowramma, Manal Mohammed, R. Kalirajan, L. Kaviarasan. Translational Chemotherapy for triple negative Breast Cancer - A Review on significance of poly (ADP-ribose) polymerase 1 (PARP 1) inhibitors. Research J. Pharm. and Tech. 2019; 12(6):3098-3104. doi: 10.5958/0974-360X.2019.00524.9   Available on: https://rjptonline.org/AbstractView.aspx?PID=2019-12-6-87


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available